---
title: "Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292895134.md"
description: "Moderna has dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf cancer antigen therapy for solid tumors. The study aims to assess the safety and tolerability of mRNA-4200 when administered with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors. mRNA-4200 encodes seven shared tumor antigens designed to induce and expand T-cell responses across multiple tumor types."
datetime: "2026-07-16T11:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292895134.md)
  - [en](https://longbridge.com/en/news/292895134.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292895134.md)
generator: "portal-rs"
---

# Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumors

-   Moderna dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf tumor-targeted cancer antigen therapy for solid tumors. \* Study will assess safety and tolerability of mRNA-4200 given with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors. \* mRNA-4200 encodes seven shared tumor antigens, aiming to induce and expand T-cell responses across multiple tumor types. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607160700ACCESSWRNAPR\_\_\_\_\_1190971) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md)
- [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md)
- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**